Counsyl, a company that screens DNA to determine if someone is a genetic carrier of certain diseases, has raised $28 million in Series D financing. The round was led by Rosemont Seneca Technology Partners and Goldman Sachs. The new funds will be used to continue investment in product development, and bring Counsyl's to-date total financing to $93 million.
Counsyl’s new screen of cancer susceptibility genes BRCA1 and BRCA2 informs men and women if they have inherited a high risk for breast, ovarian, prostate and pancreatic cancers. Along with its cancer screenings, the company also provides a family-planning screening.